Ken Griffin Ocuphire Pharma, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 19,000 shares of OCUP stock, worth $18,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,000
Previous 13,700
38.69%
Holding current value
$18,620
Previous $13,000
38.46%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding OCUP
# of Institutions
50Shares Held
17.6MCall Options Held
19KPut Options Held
0-
Perceptive Advisors LLC New York, NY4.33MShares$4.24 Million0.19% of portfolio
-
Bios Capital Management, LP Fort Worth, TX3.68MShares$3.61 Million4.77% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.35MShares$3.28 Million0.14% of portfolio
-
Opaleye Management Inc. Boston, MA1.22MShares$1.2 Million0.29% of portfolio
-
Mink Brook Asset Management LLC West Palm Beach, FL1.2MShares$1.17 Million0.98% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...